TY - JOUR T1 - Impact of SARS-CoV-2 B.1.1.7 Spike variant on neutralisation potency of sera from individuals vaccinated with Pfizer vaccine BNT162b2 JF - medRxiv DO - 10.1101/2021.01.19.21249840 SP - 2021.01.19.21249840 AU - DA Collier AU - B Meng AU - IATM Ferreira AU - R Datir AU - The CITIID-NIHR BioResource COVID-19 Collaboration AU - N Temperton AU - A Elmer AU - N Kingston AU - B Graves AU - LE McCoy AU - KGC Smith AU - Bradley, JR AU - J Thaventhiram AU - L Ceron-Gutierrez AU - G Barcenas-Morales AU - M Wills AU - R Doffinger AU - RK Gupta Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/20/2021.01.19.21249840.abstract N2 - SARS-CoV-2 transmission is uncontrolled in many parts of the world, compounded in some areas by higher transmission potential of the B1.1.7 variant now seen in 50 countries. In addition, many countries are extending the interval between doses of vaccine is being extended in order to expand vaccine coverage. It is unclear whether real world neutralising antibody titres will follow those in clinical trials, particularly in elderly persons, and how this will be impacted by mutations in strains such as B1.1.7. Here we tested immune responses in patients 3 weeks following the first dose of the Pfizer BioNTech vaccine BNT162b2. We also tested neutralising antibody responses against pseudoviruses expressing wild type Spike proteins or expressing 3 key mutations present in B.1.1.7 (deletion 69/70, N501Y, A570D). IgG Spike antibody titres correlated well with neutralisation. We observed a range of neutralisation titres against wild type, with geometric mean titre (GMT) of 24. The vaccine sera exhibited a range of inhibitory dilutions giving 50% neutralisation (ID50) from <1:4 to 3449. However a lower proportion of participants over 80 years old achieved threshold neutralisation titre of >1:4 for 50% neutralisation as compared to those under 80 years old (8/15 versus 8/8 P=0.052) after the first dose. Neutralisation titres were not significantly impacted by the combination of three Spike mutations tested, but were reduced against the full set of Spike mutations present in the B.1.1.7 variant. The highest fold change was approxiamately 6 and the median fold change for the B.1.1.7 variant versus wild type was 3.85 (IQR 2.68-5.28). Further work is needed to establish the impact of these observations on real life vaccine efficacy.Competing Interest StatementRKG has received consulting fees from UMOVIS LabFunding StatementThis research was supported by the National Institute for Health Research Cambridge Biomedical Research Centre. RKG is supported by a Wellcome Trust Senior Fellowship in Clinical ScienceAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the East of England Cambridge Central Research Ethics Committee 17 EE 0025.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available from the corresponding author on request ER -